Please login to the form below

Not currently logged in
Email:
Password:

ertugliflozin

This page shows the latest ertugliflozin news and features for those working in and with pharma, biotech and healthcare.

The year of the blockbuster

The year of the blockbuster

Steglatro (ertugliflozin) from Pfizer and Merck:Sodium glucose co-transporter-2 (SGLT-2) inhibitors are the newest oral treatment options for diabetes, but SGLT-2 inhibitor Steglatro will be a late

Latest news

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    60. Pfizer/ Merck &Co. Collaboration. Ertugliflozin as standalone and combination with Januvia and/or metformin for diabetes.

  • Pharma deals during April 2013 Pharma deals during April 2013

    The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics